Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
The New England Journal of Medicine|February 20, 2019
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaBrian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
The Lancet. Oncology|March 20, 2025
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trialThomas Powles, Toni K Choueiri, Laurence Albiges, et al.
The Lancet. Oncology|March 1, 2023
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label studyToni K Choueiri, Masatoshi Eto, Robert Motzer, et al.
The New England Journal of Medicine|June 3, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Mats Jerkeman, et al.
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
The New England Journal of Medicine|August 18, 2021
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell CarcinomaToni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
The New England Journal of Medicine|April 17, 2024
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell CarcinomaToni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
The New England Journal of Medicine|August 21, 2024
Belzutifan versus Everolimus for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Katriina Peltola, et al.
The New England Journal of Medicine|February 22, 2021
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Boris Alekseev, Sun-Young Rha, et al.
Blood|July 21, 2020
Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R Mato, Lindsey E Roeker, Nicole Lamanna, et al.
Pageof 14